TSX closed
Loading markets…

Advertisement

Stocks

Will Medexus Pharmaceuticals Inc (MDP) Beat Estimates Again in Its Next Earnings Report?

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:MDP.TO

Get MDP alerts:

Photos provided by Pexels

As Medexus Pharmaceuticals prepares to report its fiscal Q4 2026 results, investors are keenly interested in whether the company can continue its trend of exceeding earnings expectations.

Scheduled for after market close on August 10, 2026, Medexus Pharmaceuticals Inc (MDP.TO) is set to release its earnings for the quarter ending June 30, 2026. With a consensus EPS estimate of 0.11, the upcoming report will be closely scrutinized given the company's recent performance history, which includes three earnings beats in the last four quarters.

Recent earnings trend

Advertisement

Medexus Pharmaceuticals Inc

MDP.TO

Full stock page →

MDP.TO

Medexus Pharmaceuticals Inc

Source:WealthAwesomeWealthAwesome
$1.95 (63.31%)
120 day period
$3.04$4.25$5.45Mar 27Jun 23Sep 17

Market cap

$157.13M

52W high

$5.50

52W low

$2.51

1W change

-1.57%

Beta

1.83

Analyst Price Targets

Based on analyst covering MDP · as of Sep 17, 2026

📈

Wall Street analysts forecast MDP stock price to rise 45.0% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.25

+45.0% Upside

Current Price

C$5.00

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on MDP's historical volatility

HistoricalForecast68%95%
C$3.71C$4.75C$5.80C$6.85C$7.90C$8.95TodayMay 11Jul 15Sep 17Oct 30Dec 13Jan 25

30-Day Vol

30.8%

Annualized

90-Day Vol

38.9%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$6.01

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$5.34C$4.80C$5.94
60 trading daysC$5.67C$4.87C$6.59
90 trading daysC$6.01C$5.00C$7.23

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.

Beat estimates in 3 of the last 4 comparable quarter(s).

Fiscal periodReport dateActual EPSEstimateSurprise
2026-06-302026-08-100.1100
2026-03-312026-06-25-0.11350.0100-1235.0%
2025-12-312026-02-110.0034-0.0400+108.5%
2025-09-302025-11-12-0.0100-0.0700+85.7%
2025-06-302025-08-120.0100-0.0800+112.5%
2025-03-312025-06-26-0.0259-0.1300+80.1%
-0.13000.01000.1500 24-0624-0924-1225-0325-0625-0925-1226-03 Estimate Actual (≥0) Actual (<0) Wealth Awesome

Advertisement

Investor takeaway: Investors should watch for Medexus's ability to maintain momentum, especially considering its strong product-level performance with GRAFAPEX. The potential for significant EPS growth of 245.3% year-over-year could influence market sentiment and share price movements.

EPS Estimate of 0.11, with a Year-Over-Year Growth Projection of 245.3%

The anticipated EPS growth reflects a significant turnaround from the prior year, indicating strong operational improvements and potential for enhanced profitability, but also raises expectations for the upcoming report.

Bull case

If Medexus can meet or exceed the EPS estimate of 0.11, it would boost investor confidence and could lead to a positive re-rating of the stock. The company has shown resilience, with strong product performance and a bullish analyst target of C$6.81, suggesting substantial upside.

Bear case

On the other hand, if Medexus falls short of expectations, especially after a recent EPS revision downwards from 0.13 to 0.10, it could trigger a negative reaction in the stock. Investors may also be cautious due to the company's recent history of volatility in earnings surprises.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 10, 2026
Last Updated: August 10, 2026
PARTNER SPOTLIGHT

Blue Cross Life® Term Life Insurance

Affordable term life coverage in Canada — get a free quote in seconds, no credit card required.

  • Coverage from $100,000 to $5 million, terms of 10–30 years
  • 10% off first-year premiums when couples apply together
  • Fully digital application — many qualify without a medical exam

Sponsored links

Advertisement